Jefferies keeps Buy on Siemens Healthineers stock with EUR 50 target
Published on 10/01/2026 at 11:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Siemens Healthineers (ISIN DE000SHL1006) was trading at EUR 37.60 at Lang & Schwarz on October 1, 2026 at 11:06 a.m. CEST, down 0.69 percent from the EUR 37.86 prior close. Jefferies kept its Buy rating and EUR 50.00 price target on September 30, 2026, linking the view to the Accela radiotherapy platform.
Jefferies sees EUR 50 target
According to finanzen.ch on September 30, 2026, Jefferies retained Buy and a EUR 50.00 target after reviewing Siemens Healthineers ahead of the November 5 results.
The EUR 50.00 target lies 32.98 percent above the EUR 37.60 Lang & Schwarz price. Jefferies analyst Julien Dormois said Accela could support Varian's market-share position, while the financial contribution is expected to build in fiscal 2027 and fiscal 2028.
Third-quarter figures beat forecasts
Investing.com lists revenue of EUR 5.76 billion against EUR 5.65 billion forecast for the fiscal third quarter of 2026, while earnings per share reached EUR 0.70 against EUR 0.53 forecast. The comparison gives the stock a stronger earnings reference than the daily price move alone.
The same earnings page identifies the latest release as July 31, 2026. Siemens Healthineers' fiscal third-quarter report covers the period ended June 30, 2026, keeping the reported figures inside the current reporting window.
Buyback adds a second support
According to EQS News on September 28, 2026, Siemens Healthineers repurchased 160,000 shares between September 21 and September 27, bringing cumulative purchases since June 1 to 3,374,359 shares.
The buyback provides a quantified capital-allocation signal, while the Accela thesis remains tied to regulatory approvals, installation and production ramp-up. That timing explains why the analyst case emphasizes a gradual contribution rather than an immediate earnings step-up.
Next test comes November 5
Investing.com names November 5, 2026 as the next earnings date. The report will give investors a fresh measure of the fiscal 2026 outlook and the pace of improvement in imaging and diagnostics.
Stock remains below yearly high
Siemens Healthineers was valued at EUR 41.9 billion on October 1, 2026. Its 52-week range was EUR 32.81 to EUR 49.71 as of September 30, 2026, placing the Lang & Schwarz price EUR 12.11 below the reported high.
At 11:06 a.m. CEST, the stock was trading at EUR 37.60 at Lang & Schwarz on October 1, 2026, down 0.69 percent versus the Lang & Schwarz prior close of EUR 37.86 on September 30, 2026. The further course of trading is shown by the continuously updated real-time quote of Siemens Healthineers stock.
Siemens Healthineers stock facts
- Company: Siemens Healthineers AG
- ISIN: DE000SHL1006
- WKN: SHL100
- Ticker: SHL
- Primary exchange: Xetra
- Price Lang & Schwarz (as of October 1, 2026, 11:06 a.m. CEST): EUR 37.60
- Change versus prior close: minus 0.69 percent
- Prior close Lang & Schwarz (September 30, 2026): EUR 37.86
- Market capitalization: EUR 41.9 billion (as of October 1, 2026)
- 52-week range: EUR 32.81-EUR 49.71 (as of September 30, 2026)
- Sector / Industry: Healthcare / Healthcare Equipment and Supplies
- Index membership: DAX and TecDAX
- Next earnings date: November 5, 2026
